Natera (NASDAQ:NTRA) Insider John Fesko Sells 931 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 931 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total value of $236,539.17. Following the completion of the transaction, the insider directly owned 184,069 shares in the company, valued at $46,766,410.83. The trade was a 0.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92.
• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $59,992.56.

Natera Stock Performance

NTRA opened at $253.82 on Thursday. The firm’s fifty day moving average is $244.16 and its two-hundred day moving average is $221.65. The firm has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its stake in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares during the last quarter. NewEdge Advisors LLC raised its holdings in Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the period. Focus Partners Wealth raised its holdings in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Natera during the second quarter worth approximately $558,000. Institutional investors own 99.90% of the company’s stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
• Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NTRA shares. The Goldman Sachs Group assumed coverage on Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price for the company. Barclays decreased their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.